182
0,78
1,36
43% reduction in clinically significant
exacerbations* over 52 weeks
Efficacy was analyzed in 576 patients
(modified intent‐to‐treat population)
*Defined as worsening of asthma symptoms requiring
doubling of baseline ICS dose and/or treatment with rescue
systemic corticosteroids for >3 days.
ICS = inhaled corticosteroids; RRR = relative risk reduction.
Lanier B,
et al. J Allergy Clin Immunol
2009;124:1210–6.
p<0.001
Omalizumab
(n=384)
Placebo
(n=192)
52-week treatment period
Clinically significant exacerbation rate
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
RRR
43%
IA05
Omalizumab in children with allergic
asthma
1
LanierB,
etal
.
JAllergyClinImmunol
2009;124:1210–6;
2
KulusM,
etal
.
CurrMedResOpin
2010;26:1285–93;
3
MilgromH,
etal
.
Pediatrics
2001;108:e36;
4
BusseW,
etal
.
NE
n
glJMed
2011;364:1005–15
IA05
1
Omalizumab reduced clinically
significant exacerbations
over 52 weeks in children with
moderate‐to‐severe allergic
asthma
Severe
N=246
Exacerbations
52 Weeks
IA05-EU
2
Moderate‐to‐severe
(well controlled)
N=334
Steroid sparing
28 Weeks
010
3
Persistent asthma
(any severity)
N=419
Symptom‐free days
60 Weeks
ICATA
4
Simposium
